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Eliminating prophylactic antibiotics in food animal production has exerted pressure on 
discovering antimicrobial alternatives (e.g. microbiome) to reduce elevated intestinal diseases. 
Intestinal tract is a complex ecosystem coupling host cells with microbiota. The microbiota and 
its metabolic activities and products are collectively called microbiome. Intestinal homeostasis is 
reached through dynamic and delicate crosstalk between host immunity and microbiome. 
However, this balance can be occasionally broken, which results in intestinal inflammatory 
diseases such as human Inflammatory Bowel Diseases, chicken necrotic enteritis, and swine 
postweaning diarrhea. In this review, we introduce the intestinal immune system, intestinal 
microbiome, and microbiome modulation of inflammation against intestinal diseases. The 
purpose of this review is to provide updated knowledge on host-microbe interaction and to 
promote using microbiome as new antimicrobial strategies to reduce intestinal diseases. 
 






World Health Organization (WHO) defines antimicrobial resistance as “the ability of a 
microorganism (like bacteria, viruses, and some parasites) to stop an antimicrobial (such as 
antibiotics, antivirals, and antimalarials) from working against it” (WHO, 2018a). Urgency is 
mounting to reduce antimicrobial resistance from agriculture to healthcare because of the 
emergency of “superbug” bacteria resistant to antibiotics (e.g. colistin) in treating multidrug-
resistant (MDR) infections (CDC, 2018; McGann et al., 2016). It is estimated that 558,000 new 
tuberculosis (TB) worldwide in 2017 were resistance to rifampicin, which is the most effective 
first-line antibiotics (WHO, 2018b). Among them, 82% were MDR-TB. Overuse and misuse of 
antimicrobial agents in medical and agricultural practice contribute to exacerbating the episodes 
of emerging antimicrobial resistant microbes (Makary et al., 2018; Martens and Demain, 2017; 
Neu, 1992; Van Puyvelde et al., 2018). A recent systematic review found that restricting the use 
of antibiotics reduces antibiotic-resistant bacteria by 10–15% in animal studies or by 24% in 
human studies (Tang et al., 2017). 
 
Withdrawing antimicrobials in food animal production, however, has caused new problems for 
the food animal industries including reducing production efficiency and increasing intestinal 
diseases, such as necrotic enteritis (NE) in poultry (Casewell et al., 2003) and postweaning 
diarrhea in piglets (Rhouma et al., 2015). Doubling of incidences in subclinical NE 
(cholangiohepatitis) from 2013 to 2014 in south-eastern Norway were associated with reduced 
in-feed antimicrobial usage (Kaldhusdal et al., 2016), although no major worldwide clinical NE 
outbreak has recently been reported. Although the use of antibiotics as antimicrobial growth 
promoter (APG) in food animal production is thought to inhibit intestinal microbial overgrowth, 
it has been suggested that antibiotics may also act as direct anti-inflammatory agents (Niewold, 
2007). Interestingly, antibiotics have limited effect on treating human inflammatory intestinal 
diseases, such as Inflammatory Bowel Disease (IBD) and refractory Clostridium difficile 
infection (CDI). Recently, reconstituting intestinal microbiome has shown promise on preventing 
and treating some intestinal diseases. For example, refractory CDI patients who can’t be cured 
with antibiotics have been successfully treated with fecal microbiota transplantation (FMT) 
(Silverman et al., 2010). A recent meta-analysis showed that 92% of CDI patients have clinically 
resolved the symptoms after FMT without serious adverse events (Quraishi et al., 2017). The 
introduction of donor fecal microbiota increases the diversity of the microbiome and alters the 
metabolic pathways active in the intestinal microbiota (Shankar et al., 2014). FMT against IBD 
remains controversial with some reporting remission in active ulcerative colitis (UC) patients at 
clinical and endoscopic levels (Jeon et al., 2018; Moayyedi et al., 2015), while others show little 
to no efficacy (Ianiro et al., 2014; Kump et al., 2013; Rossen et al., 2015). The underlying 
mechanisms of microbiome manipulation treating intestinal diseases are multiple facets 
involving delicate interactions between microbiome, immunity, and pathogens. Here, we will 
summarize recent progress on the intestinal microbiome, the intestinal immune system, and 
microbiome modulation against intestinal diseases. The aim of this review is to promote the use 
of microbiome as a new antimicrobial strategy to reduce intestinal diseases. 
 
2. Intestinal immune system 
 
The gastrointestinal tract is essential for providing the nutritional needs of a body through 
digesting food/feed and absorbing nutrients. Luminal food and microbes are separated from the 
internal tissue by a single layer of intestinal epithelial cells (IEC), including enterocytes, goblet 
cells, Paneth cells, enteroendocrine cells, microfold cells (M cells), and stem cells (Carulli et al., 
2014). Besides as a physical barrier, IEC also secrets antimicrobial peptides (AMPs) and mucin 
to control luminal microbes (Antoni et al., 2013). Underneath IEC is the intestinal lamina 
propria containing a diverse array of immune cells. These immune cells generally are classified 
into two main categories of adaptive and innate immune cells (Fig. 1A). 
 
 
Fig. 1. Schematic intestinal immunity. (A) Microbe induces immune response. APC: antigen 
presenting cells including dendritic cells (DC) and macrophage. Treg: regulatory T help cell. EC: 
effect cells including effector T help cells (Th) of Th1 and Th17, innate cells of Granulocytes 
(neutrophil/heterophil, eosinophil, basophil), master cell, NK cell, macrophage, DC, ILC (ILC1, 
ILC2, ILC3), intestinal epithelial cell (IEC), intestinal epithelial lymphocyte (IEL). MAMP: 
pathogen-associated molecular patterns. (B) Enlargement of pink rectangle of A. 
 
Cellular signaling pathways with emphasis on TLR/Myd88 pathway. TLR: toll-like receptor. 
NLR: NOD like receptor. RLR: RIG-I like receptor. Myd88: myeloid differentiation primary 
response 88. IKK: IκB kinase. NF-κB: nuclear factor kappa-light-chain-enhancer of activated B 
cells. PI3K: phosphatidylinositol 3-kinase. mTOR: mammalian target of rapamycin. Dotted 
arrow: indirect induction; solid arrow: direct induction; blunt end line: inhibition. 
 
Adaptive immune cells in intestine include T and B lymphocytes which are constantly shaped 
by intestinal microbiota. Naive T and B cells migrate and accumulate in gut-associated lymphoid 
tissues (GALT), including Peyer’s patches (PPs), isolated lymphoid follicles, and mesenteric 
lymph nodes (MLN) (Koboziev et al., 2010; Severson et al., 2010). The T cells then undergo 
antigen-driven priming/activation, polarization, and expansion (Agace, 2008) and the antigens 
come from microbiota, nutrients, metabolites, pollutants, and harmful pathogens. Upon priming 
within GALT, activated T cells acquire the ability to home to the intestine. CD8+ T cells migrate 
to the intestinal epithelium, while CD4+ T and B cells (mainly IgA-producing plasma cells) enter 
into the lamina propria (Mowat, 2003). It is evident that microbiota influence adaptive immunity. 
For instance, deficiency of intestinal IgA secreting plasma B cells in germ-free (GF) mice is 
rectified by introducing commensal bacteria (Shroff et al., 1995), suggesting the important role 
of microbiota on shaping B cell development. The main cell types of intestinal CD4+ T cells are 
T help cell 1 (Th1), Th17, and regulatory T cell (Treg, Foxp3-expressing) cells, although Th2, 
Th9, Th22, follicular helper T (Tfh), iTreg, and type 1 regulatory T cell (Tr1) are also reported 
(Brucklacher-Waldert et al., 2014; Kreisman and Cobb, 2011). Treg cells maintain tolerance to 
self-antigens and prevent an inflammatory response. In the gut, Treg cells maintain homeostasis 
at steady-state where the cells play an important role in the regulation of inflammation against 
intestinal microbes (Harrison and Powrie, 2013). Indeed, adoptive transfer of CD4+ T cells to 
specific pathogen free (SPF) mice in the absence of Tregs, but not in their presence, elicit 
commensal microbiota-induced colitis (Powrie et al., 1993). Thus, Tregs are critical for the 
prevention of spontaneous inflammation against commensal microbes. 
 
The importance of Treg is also evident in the case of immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, where FOXP3 is mutated. IPEX 
patients develop autoimmune enteropathy in the intestine (Bennett et al., 2001). Depletion of 
Foxp3+ Treg cells in SPF mice leads to intestinal-associated autoimmune and inflammatory 
disorders (Lahl et al., 2007), while GF mice are healthy under Tregs depletion (Feng et al., 
2010). Treg cells induce immunosuppressive functions through various mechanisms, namely, 
secreting anti-inflammatory cytokines of IL-10, IL-35, and TGF-β (Chaudhry et al., 2011; 
Collison et al., 2007; Powrie et al., 1996), metabolic pathway disruption (Deaglio et al., 2007), 
induction of apoptosis in target cells (Gondek et al., 2005), and modulating DC maturation and 
function (Mahnke et al., 2007). These actions limit the expansion of antigen-specific effector T 
cells including Th1 and Th17 cells, which induce an inflammatory response, mucosal barrier 
protection, and tissue repair (Huber et al., 2012). Th17 cell differentiation depends on the 
presence of a pro-inflammatory microenvironment of IL-23, IL-6, and IL-1β (Zuniga et al., 
2013). A specific microbiota modulates Th17 cell differentiation in the mucosa of the small 
intestine, and one group of bacteria are specific species of Clostridia-related bacteria, 
named segmented filamentous bacteria (SFB) (Ivanov et al., 2009, 2008). 
 
The activation of adaptive cells is achieved by innate cells presenting antigens (Taams et al., 
1999) and some of the most important antigens are derived from intestinal microbiota. Innate 
immune cells include dendritic cells, macrophage, neutrophil, and innate lymphoid cells (ILCs). 
Macrophages and dendritic cells (DC) are antigen presenting cells (APC), and they sample 
luminal content of food and microbiota and coordinate both innate and adaptive immune 
responses (Kayama et al., 2013). Hence, macrophage and DC determine the difference between 
innocuous and pathogen-derived antigens and induce either pro- or anti-inflammatory processes. 
In mice with antibiotics-induced dysbiosis, CX3CR1+ macrophages up-regulate CCR7 and 
migrate to mesenteric lymph nods, where the cells present antigens to induce T-cell responses 
and the differentiation of IgA-producing B cells (Diehl et al., 2013). Colonic macrophages from 
GF mice have enhanced proinflammatory cytokine responses (Ueda et al., 2010). Microbiota 
metabolizing bile acids mediates liver tumor growth through mobilizing natural kill T cells (Ma 
et al., 2018). These findings highlight the critical role of microbiota shaping innate immunity. 
Another important group of innate cells is ILCs which have been classified into three subtypes of 
ILC1, ILC2, and ILC3, based on their cytokine production and expression of 
determined transcription factors (Eberl et al., 2015). Because of their similarities, ILCs are 
considered the innate counterpart of T helper cells of Th1, Th2, and Th17 (von Burg et al., 
2015). The activity of these ILCs is modulated by many tissue-specific cues, including nutrients, 
environmental xenobiotics, and microbiota (Kiss et al., 2011; Spencer et al., 2014; van de Pavert 
et al., 2014). Notably, IL-22 secretion from ILC3 is negatively influenced by intestinal 
microbiota-promoted IL-25 secretion from epithelia cells (Sawa et al., 2011). IL-17 promotes 
local chemokine production to recruit monocytes and neutrophils to sites of inflammation to 
mediate protection against pathogens, especially against extracellular pathogens (Korn et al., 
2009). 
 
Innate immune cells recognize microbial pathogen invasion or host cell damage with 
intracellular or surface-expressed pattern recognition receptors (PRR) (Fig. 1B). PRR detect 
microbe-associated molecular patterns (MAMP), such as microbial nucleic acids, lipoproteins, 
and carbohydrates or damage-associated molecular patterns (DAMP) released from injured cells 
including ATP, the cytokine IL1a, uric acid, the calcium-binding cytoplasmic proteins S100A8 
and S100A9, and the DNA-binding nuclear protein HMGB1 (Akira et al., 2006; Schaefer, 2014). 
Members of the toll-like receptor (TLR) family are major PRR in cells. Upon activation by 
microbial components, all TLRs except TLR3 recruit Myeloid differentiation primary response 
88 (MyD88) with/without Toll/interleukin-1 receptor (TIR) domain-containing adapter 
protein/MyD88 adapter-like (TIRAP/Mal) (Deguine and Barton, 2014). Intestinal microbiota 
even drives systemic neutrophil inflammatory response through MyD88 signaling pathways 
(Karmarkar and Rock, 2013). In turn, MyD88 signaling in T cell modulates IgA secretion and 
controls gut microbiota composition to protect host (Kubinak et al., 2015). TLR/MyD88 
downstream targets include transforming growth factor beta-activated kinase 1 (TAK1)/ IκB 
kinase (IKK)/nuclear factor κ light chain enhancer of activated B cells (NF-κB) signaling, 
TAK1/p38α and JNK, and Phosphatidylinositol 3-kinase (PI3K)/ mammalian target of 
rapamycin (mTOR) (Brown et al., 2011; Jobin and Sartor, 2000; Kawasaki and Kawai, 2014). 
Transcription factors of NF-κB, p38α, and JNK regulates various intestinal cell homeostasis and 
inflammation in response to host activities and microbial stimuli (Huang et al., 2009; Jobin et al., 
1999). 
 
Another family of PPR includes retinoic acid-inducible gene 1 (RIG-I) like receptor (RLR) 
including RIG-I, melanoma differentiation-associated protein 5 (MDA5), and laboratory of 
genetics and physiology 2 (LGP2) (Loo and Gale, 2011).(Loo and Gale, 2011). RLR induces 
production of pro-inflammatory cytokines and type I IFN in response to viral and bacterial 
nucleic acids in the cytoplasm (Takeuchi and Akira, 2010). Intestinal microbiota of virus 
activates RIG-I signaling and reduces colitis-associated colorectal cancer (Zhu et al., 2017). 
(Takeuchi and Akira, 2010). Members of the Nod-like receptor (NLR) family of cytosolic PRR 
mediate NF-κB activation through Nucleotide-binding oligomerization domain-containing 
protein (NOD)1 and NOD2 or regulate secretion of the pro-inflammatory cytokines IL1β and 
IL18 through inflammasomes such as NLR family pyrin domain containing 3 (NLRP3) (Franchi 
et al., 2009).(Franchi et al., 2009). NOD2 mutations are associated with Crohn’s Disease (one 
type of IBD) and Blau syndrome (Caso et al., 2015), whereas mutations in the CIAS1 (encoding 
NLRP3) are associated with familial cold autoinflammatory syndrome, Muckle-Wells syndrome, 
and neonatal-onset multisystem inflammatory disease (Ahmadi et al., 2011). Intestinal 
microbiota sensed by NOD2 is essential for maintaining the homeostasis of intestinal 
intraepithelial lymphocytes (Jiang et al., 2013). Hyperactive NLRP3 induced IL-1β production 
shapes intestinal microbiota to boost Tregs in intestinal lamina propria and resists against 
intestinal inflammation (Yao et al., 2017). 
 
3. Specific members of the microbiome on gut function and immunity 
 
The intestine harbors a complex community of trillions of microbes including bacteria, archaea, 
virus, and eukarya. These microbes called microbiota, and their metabolic activities and products 
are collectively defined as the microbiome. The hosts tolerate and form a symbiosis relationship 
the microbiome (Neish, 2009). The tolerance is mediated through suppressing host immune 
inflammatory response toward the microbiome. In gut lamina propria, intestinal CD103+ DCs 
sense microbiota and its products, become tolerogenic and induce FoxP3+ Tregs by stimulating 
CCR7 and integrin-αIVβ7 on T cells resided in mesenteric lymph nods (Johansson-Lindbom et al., 
2005; Sun et al., 2007; Worthington et al., 2011). The important role of Tregs on sustaining 
tolerance to microbiome is clearly demonstrated where colitis is developed in CD4+ transferred 
SPF mice without Tregs, while no colitis occurs with Tregs (Powrie et al., 1993). The host also 
actively interacts with microbiome to maintain friendly microbiota composition through 
secretion of mucin, IgA, and antimicrobial peptides (Caballero and Pamer, 2015; Shapiro et al., 
2014; Vaishnava et al., 2011). Specific members of microbiota play an important role in shaping 
host health and disease at the local gut and extraintestinal systematic levels. A human 
commensal bacterium Bacteroides fragilis induces Tregs development in the mouse intestine 
(Round et al., 2011). Clostridia-related bacteria SFB promote Th17 cell differentiation in 
the mucosa of mouse small intestine, and the cells protect host against enteropathogenic and 
enterohemorrhagic (EPEC) Citrobacter rodentium (counterpart of human pathogen EPEC E. 
coli) infection in the intestine (Ivanov et al., 2009). At a systematic level, higher abundance of 
intestinal butyrate-producing genus Odoribacter has been found to associate with lower blood 
pressure in overweight and obese pregnant women (Gomez-Arango et al., 2016). Clinical 
severity of rheumatoid arthritis is associated with the abundance of Lactobacillus salivarius in 
the patients’ intestine and oral cavity (Zhang et al., 2015). 
 
Besides gut microbiota modulates host immune response, its constituents are influenced by a 
variety of factors such as host, age, diet, and others. Despite of mice are frequently utilized to 
model human microbiota, the similarity of microbiota population between humans and other 
animals is dog > pig > mice (Coelho et al., 2018). Host T cells modulate IgA secretion through 
MyD88 and shapes gut microbiota to protect itself (Kubinak et al., 2015). The composition of the 
healthy adult human microbiota is identified with 2172 prokaryotic species, and 12 different 
phyla and 93.5% of phyla are Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria 
(Hugon et al., 2015). Diets influence the spatial distribution of microbiota by providing available 
nutrients. At ileum, microbiota is colonized with microbes capable of utilizing simple sugars 
such as Streptococcus sp., Escherichia coli, Clostridium sp. and high G + C organisms 
(Zoetendal et al., 2012). Colonic microbiota is driven by the availability of microbiota-accessible 
polysaccharides in dietary fiber. Short term animal-based diet increases the abundance of bile-
tolerant microorganisms of Alistipes, Bilophila, and Bacteroides but decreases the ratio of 
Firmicutes of Roseburia, Eubacterium rectale and Ruminococcus bromii that metabolize dietary 
plant polysaccharides (David et al., 2014). The constituents of microbiota evolve with aging. The 
intestinal microbiota of neonates has low diversity and is mainly phyla Proteobacteria and 
Actinobacteria, but Firmicutes and Bacteroidetes become dominant with aging (Koenig et al., 
2011; Yatsunenko et al., 2012). Various factors influence infant microbiota development 
including preterm bird, mode of delivery, infant diet, antibiotic use, environment and lifestyle, 
host genetics (Dominguez-Bello et al., 2010; Fouhy et al., 2012; Grzeskowiak et al., 2012; 
Koboziev et al., 2010; Turnbaugh et al., 2009; Wang et al., 2009). The microbiota of a 2.5-year-
old toddler is comparable to that of an adult in terms of composition and diversity (Koenig et al., 
2011), suggesting a relatively quick and regulated assembly of infant microbiota. 
 
 
Fig. 2. Intestinal microbiome on immunity and pathogen. Solid/dotted arrow: direct/indirect 
induction; blunt end dotted line: indirect inhsibition; blunt end solid line: direct inhibition. 
AhR: aryl hydrocarbon receptor. 
 
The intestinal microbiota generates a variety of bioactive metabolites after metabolizing nutrients 
from diets and host secretion (Fig. 2). These microbial metabolites are actively engaged with 
gastrointestinal function and immunity. For example, short chain fatty acids (SCFA) are the early 
finding of microbiota metabolic products with level as high as 131 mM in human colon content 
(Cummings et al., 1987; Macfarlane and Macfarlane, 2003). The most abundant SCFA is 
propionate, butyrate, and acetate typically at a ratio of 1:1:3 (Tazoe et al., 2008). Intestinal 
epithelial cells rapidly absorb the SCFA which regulates a variety of cellular events including 
gene expression, chemotaxis, differentiation, proliferation and apoptosis (Correa-Oliveira et al., 
2016). For regulating immunity, butyrate induces colonic Treg cells (Furusawa et al., 2013) and 
protects against inflammatory response and tumorigenesis (Lin and Zhang, 2017; Morrison and 
Preston, 2016). Specifically, intestinal macrophages and DCs sense butyrate via the niacin 
receptor GPR109a, and lead to elevated IL-10 production, up-regulated retinaldehyde 
dehydrogenase enzymes, and enhanced Treg cell differentiation (Singh et al., 2014). For 
supporting intestinal epithelial growth, butyrate was used by colonocytes as an important energy 
source (Correa-Oliveira et al., 2016). SCFA also attenuates bacterial invasion by modulating gut 
barrier function, mucin secretion, and inflammatory response (Morrison and Preston, 2016). 
Besides SCFAs directly interact with and benefit host, they inhibit microbial growth. Various 
short-chain carboxylic acids are used as food/feed preservative, and butyrate reduces Salmonella 
Enteritidis invasion into epithelial cells (Van Immerseel et al., 2004). SCFAs are metabolites of 
specific members of intestinal microbiota. Propionate is mainly produced in human gut by 
Bacteroidetes such as species of Bacteroides uniformis, Prevotella copri, and Alistipes putredini, 
while the majority of butyrate is generated by Firmicutes including species of Roseburia 
intestinalis, Eubacterium rectale, Coprococcus eutactus, and Subdoligranulum variabile (Louis 
and Flint, 2017). Hence, it is possible that colonizing the butyrate-producing bacteria such as 
Roseburia intestinalis may increase IL-17 production against intestine bacterial (e.g., E. coli, 
Salmonella) infection in human and animals. 
 
Another group of microbial metabolites with high intestinal concentration are bile acids at 3–
30 mM in the human small intestine (Darkoh et al., 2010). Bile acid generation is the primary 
pathway for cholesterol catabolism and accounts for 50% daily cholesterol turnover (Insull, 
2006). Primary bile acids of cholic acid (CA) and chenodeoxycholic acid (CDCA) are 
synthesized from cholesterol in hepatocytes and conjugated with glycine or taurine (Chiang, 
2004). In the intestine, the conjugated primary bile acids are deconjugated by bacterial bile 
salt hydrolase (BSH) and further altered by microbiota to produce secondary bile acids 
including lithocholic acid (LCA), deoxycholic acid (DCA), and ursodeoxycholic acid (UDCA). 
Besides emulsification of lipid for digestion, bile acids are implicated in various signaling 
pathways including nuclear receptors of farnesoid X receptor (FXR) (Wang et al., 1999), 
pregnane X receptor (PXR) (Xie et al., 2001), and vitamin D receptor (VDR) (Makishima et al., 
2002), as well as G protein-coupled receptors of G-protein-coupled bile acid receptor (TGR5) 
(Maruyama et al., 2002) and sphingosine-1-phosphate receptor 2 (S1P2) (Studer et al., 2012). 
CDCA in humans or CA in mice is the most potent FXR ligand, while DCA and LCA are 
preferential ligands for TGR5 and membrane-type receptor for bile acids (Chiang, 2009; 
Maruyama et al., 2002). DCA and LCA also activate PXR and VDR (Chiang, 2009). These 
signaling pathways regulate hepatic lipid, glucose, and energy homeostasis and maintain 
metabolic homeostasis. Both TGR5 and FXR are expressed by circulating monocytes and 
macrophages isolated from intestine and liver, and activation of the signaling pathways 
attenuates inflammatory response (Cipriani et al., 2011; Mencarelli et al., 2009; Vavassori et al., 
2009). DCA and LCA induced TGR5 signaling reduces the accumulation and activation of 
macrophages in aortic plaques and adipose tissues through mechanisms of mTOR-induced 
C/EBPβ differential translation (Perino et al., 2014). However, it remains elusive how important 
it is during health and diseases that host responds to different bile acid species such as CA vs. 
DCA or LCA vs. DCA. Besides bile acids influence host response, their level is associated 
with microbial community dynamics in the gut (Ridlon et al., 2014). Bile acids directly inhibit 
gut microbes (Begley et al., 2005) and indirectly modulate microbiota through FXR-induced 
antimicrobial peptides (Inagaki et al., 2006). Mice fed CA have increased class Clostridia (70 vs. 
39%) compared to control mice, and genus Blautia (including Ruminococcus spp. and 
Clostridium cluster XIVa) expands from 8.3 to 55–62% (Islam et al., 2011). Deconjugating 
enzyme BSH is present in all major bacterial divisions and archaeal species in the human gut 
including members of genus Lactobacilli, Bifidobacteria, Clostridium, and Bacteroides (Archer 
et al., 1982; Gilliland and Speck, 1977; Jones et al., 2008; Ridlon et al., 2006). Secondary bile 
acid producing bacteria consist of a small population of genus Clostridium, including C. 
scindens, C. hiranonis, C. hylemonae (Clostridium cluster XVIa), and C. sordelli (Clostridium 
cluster XI) (Ridlon et al., 2006). The bile acid-metabolizing bacteria sun as Lactobacilli and 
Bifidobacteria are probiotics and they enhance health by promoting host immune homeostasis 
(Vlasova et al., 2013). 
 
Amino acid tryptophan is an important nutrient for both host and microbiota. Xenobiotic aryl 
hydrocarbon receptor (AhR) is an evolutionarily conserved receptor recognizing environmental 
compounds. AhR ligands include tryptophan metabolites of kynurenine (Mezrich et al., 2010) 
and kynurienic acid (DiNatale et al., 2010) from hosts as well as indole-3-acetate, indole-3-
aldehyde, indole, and tryptamine (Hubbard et al., 2015) from microbiota. Dietary ingredients 
from plants also contain AhR ligands such as flavonoids, stilbenes, carotenoids, and some 
indoles (Busbee et al., 2013). AhR expressed on RORγt + ILC3 is essential for their expansion 
(Kiss et al., 2011). AhR ligands of microbiota tryptophan metabolites induce IL-22 production 
and the secretion of the anti-microbial peptides lipocalin-2, S100A8, and S100A9 against 
Candida albicans infection (Zelante et al., 2013). Other amino acid metabolites with immune 
bioactivity are polyamines including putrescine, spermidine, and spermine. Polyamines regulate 
differentiation of immune cells as well as inflammation (Moinard et al., 2005), and they suppress 
pulmonary immunologic and intestinal allergic responses (Hoet and Nemery, 2000). Diet 
ingredients of fruit, cheese, vegetable, meat, and milk are rich in polyamine contents. Most 
dietary polyamines are absorbed in the small intestine (Uda et al., 2003), while intestinal 
microbiota produces polyamines in the colon (Matsumoto et al., 2012). Spermine reduces 
inflammatory cytokine expression in immune cells (Zhang et al., 1997). Microbiota-associated 
metabolites, such as spermine, histamine, and taurine, regulates host response by activating 
NLRP6 inflammasome signaling, epithelial IL-18 secretion, and downstream anti-microbial 
peptides (Levy et al., 2015). 
 
4. Microbiome modulates immunity against intestinal inflammatory diseases 
 
Despite different etiologies, intestinal diseases in human and animals, such as human IBD, CDI, 
and campylobacteriosis, chicken necrotic enteritis, and swine postweaning diarrhea share 
common features of extensive intestinal inflammation (Lippert et al., 2009; Matricon, 2010; 
Olkowski et al., 2006; Shen, 2012; Xiao et al., 2014) and disturbed microbiota (Antharam et al., 
2013; Antonissen et al., 2016; Dou et al., 2017; Lupp et al., 2007; Tamboli et al., 2004). The 
intestinal inflammation is often characterized by infiltration of immune cells into lamina propria, 
depletion of goblet cells, hyperplasia of the crypt, or epithelial cell death. At cellular and 
molecular levels, proinflammatory cytokines from Th1 and Th17 cells and TLR4 signaling 
pathway drive inflammation in IBD (Oostenbrug et al., 2005; Strober and Fuss, 2011), while 
Treg cells and NOD2 signaling attenuate the inflammatory response (Eastaff-Leung et al., 2010; 
Ogura et al., 2001). Inflammation in IBD patients disturbs intestinal microbiota and increases the 
abundance of Enterobacteriaceae, including Escherichia coli and Fusobacterium (Darfeuille-
Michaud et al., 2004; Lupp et al., 2007; Ohkusa et al., 2002). However, FMT as a therapy for 
IBD remains uncertain. Some reports have showed little to no efficacy (Ianiro et al., 2014; Kump 
et al., 2013; Rossen et al., 2015), while others have found remission in active ulcerative colitis 
(UC) patients at clinical and endoscopic levels (Jeon et al., 2018; Moayyedi et al., 2015). 
Multiple factors may influence the outcome of FMT against IBD such as the composition of 
donor and recipient microbiota, age of IBD appearance, and health status of IBD patients. 
Moreover, IBD is collective diseases with limited understanding on its etiology and it would be 
more effective to treat IBD using microbiome by targeting specific and limited pathogenic 
factors. 
 
The most successful case of microbiome treatment of intestinal disease comes from treating CDI 
by FMT. Recurrent or refractory CDI patients can’t be cured with antibiotics but are successfully 
treated with FMT (Silverman et al., 2010).(Silverman et al., 2010). Later it has been found that 
secondary bile acids of Clostridium scindens metabolites contribute to the decrease of C. difficile 
growth/colonization and toxin production (Buffie et al., 2015). The role of the microbiome on 
CDI intestinal inflammation remains to be determined, although CDI induce severe colitis with 
yellowish pseudomembranous lesions (Surawicz et al., 2013). Another human infectious enteritis 
is campylobacteriosis which features with severe intestinal inflammation in human (van 
Spreeuwel et al., 1985) and animal model (Lippert et al., 2009). Innate signaling pathway of 
PI3K/mTOR induces campylobacteriosis (Sun et al., 2013, 2012), while NOD2 protects against 
it (Sun and Jobin, 2014). Remarkably, anaerobic microbiota and its metabolite DCA prevent 
campylobacteriosis through inhibiting mTOR signaling pathway in germ-free Il10−/− mice 
(Xiaolun Sun et al., 2018). The success of microbiome against CDI and campylobacteriosis is 
benefit from the available knowledge of the contributing pathogenic factors in the diseases 
(Seekatz and Young, 2014; Sun et al., 2012). 
 
Comparable to investigating human intestinal diseases, understanding the pathogenic factors and 
microbiota status is essential for successfully treating animal diseases using microbiome. It is 
still in the infantile stage of using antimicrobial alternatives such as microbiome to prevent and 
treat animal intestinal diseases. With the progress in the biomedical field, it is possible to 
“borrow” the experience from them for accelerating the findings in animal enteritis prevention 
and treatment. Compared to huge data on human microbiota and its metabolites, animal 
microbiome research is accelerating, and the results are mounting. For example, when searching 
for terms “chicken” and “microbiome” with “2014”, “2016” or “2018” on October 8, 2018 on 
Pubmed, 58, 108, or 133 papers/results, respectively, have been found. In contrast, 4792, 7191, 
and 6714 results, respectively, were showed when replacing “chicken” with “human”. These 
accumulating research results on animal microbiome will promote the advancement of using 
microbiome against animal diseases. 
 
Necrotic enteritis at chicken ileum is reproduced with sequential infection of Eimeria maxima 
and Clostridium perfringens (Williams et al., 2003). Necrotic enteritis shows as necrosis 
intestinal cells and severe inflammation (Olkowski et al., 2006) and altered microbiota 
(Antonissen et al., 2016). It remains elusive whether the dysbiosis is just a correlation or 
cause/result of necrotic enteritis. C. perfringens expresses a number of toxins such as toxin A 
and NetB (Keyburn et al., 2008), but few reports in the US show that NetB positive C. 
perfringens alone induces necrotic enteritis. Inspired from bile acids against CDI and 
campylobacteriosis, our lab recently found that microbial metabolites primary bile acid CA and 
secondary bile acid DCA attenuated necrotic enteritis-induced body weight loss, ileal 
inflammation, and intestinal cell death (Wang et al., 2018). Inhibiting C. perfringens virulence 
(growth/toxin) and inflammatory COX2 signaling by DCA and CA may contribute to necrotic 
enteritis reduction. It is necessary to further identify additional factors of the precise virulence 
factors in C. perfringens, specific host inflammatory responses, and defined members of 
microbiome in necrotic enteritis. 
 
Another food animal enteritis is swine postweaning diarrhea caused by infection and overgrowth 
of enterotoxigenic Escherichia coli (ETEC) in small intestine (Kongsted et al., 2013) and 
disturbed microbiota(Dou et al., 2017). It remains unclear whether the dysbiosis is the cause or 
result of the enteritis. Il-17 gene accumulation is increased in piglet infected with ETEC (Luo et 
al., 2015). IL-17 secreting ILC3 cells protect against infection of Citrobacter rodentium (Qiu et 
al., 2012), a murine counterpart of human enteropathogenic E. coli. Furthermore, IL-17 protects 
mice against adherent invasive E. coli strain LF82 colonization and its induction of colitis 
through promoting IL-22 (Zhang et al., 2018). As discuss in previous sections, microbiota and it 
metabolites increase IL-17 secretion (Ivanov et al., 2009; Kiss et al., 2011). Hence, 
 
microbiome (e.g. SFB, indole) could be used to enhance ILC3 or Th17 cells for attenuating 
ETEC-induced postweaning diarrhea in piglets. Indeed, FMT has been used to improve swine 
growth performance. FMT increases average daily weight gain of recipient piglets, and reduces 
diarrhea incidence of the recipients during the trial (Hu et al., 2017). Interestingly, body weight 
gain and feed efficiency have been reduced in offspring when sows and/or neonatal offspring are 
treated with FMT using microbiota from high feed efficiency pigs (McCormack et al., 2018). 
More recently, FMT to treat canine parvovirus in dogs shows faster resolution of diarrhea and 
shorter hospitalization time, while mortality isn’t improved (Pereira et al., 2018). With increasing 
understanding of the pathogenic factors in swine postweaning diarrhea, it is possible to formulate 




Given the pressure to eliminate antimicrobials in food animal regiments, it is ever more 
important than before to understand the mechanism of host-microbiota interaction and to use the 
knowledge to prevent and treat enteritis. The development and function of the intestinal 
immunity, such as adaptive and innate cell activation, is modulated by intestinal microbiota and 
its metabolic activities and products. Intestinal dysbiosis is often associated with various 
aberrant inflammatory diseases, including IBD, CDI, campylobacteriosis, chicken necrotic 
enteritis, swine postweaning diarrhea, and other diseases. Hence, it is possible to manipulate 
microbiota and/or its metabolic products for “correcting” the dysbiome and/or deviant 
inflammatory response to prevent and treat the intestinal diseases in animals and humans. 
Indeed, microbiota reconstitution by FMT is able to prevent or treat a number of intestinal 
disorders including human CDI, campylobacteriosis in mice, diarrhea in piglets, and canine 
parvovirus in dogs. Consistently, supplementing microbial metabolite of secondary bile acid 
DCA prevents campylobacteriosis in mice and necrotic enteritis in chickens. Based on the 
successful or failed examples of the microbiome intervention on intestinal diseases, it is logic to 
conclude that a better knowledge on disease etiology and microbiome status during health and 
the diseases are essential for specifically targeting the pathogenic driving factors to prevent and 
treat the intestinal diseases. With more and more recognition and participation in the field of 
microbiome and host response, the success to find antimicrobial alternatives against additional 
diseases should be within our reach. 
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